Guangdong-Hong Kong-Macao Greater Bay Area International Research Platform
for Aptamer-based Translational Medicine and Drug Discovery (HKAP)
Funding
Supported by Mainland China Government & Industry
ID (Funding Body)
PI
Title (Start-End, Project Fund)
Prof. Aiping Lyu
NSFC 81673773
(NSFC)
The role and molecular mechanism of obesity with Chinese medicine pattern of phlegm-dampness in the pathogenesis of hypertension (2017.1-2020.12, RMB590,000)
Further research on Jin Gu Lian Capsule and Ai Di Injection for new drug R&D(2015-2018, HK$ 3,200,000)
Efficacy evaluation and mechanism exploration of Pien Tze Huang on multiple sclerosis (2015.7.30-2018.07.30, HK$2,500,000)
New drug R&D for therapeutic RNAi targeting CKIP-1 to reverse bone erosion in Rheumatology Arthritis (2015-2017, RMB3,000,000)
Does aberrantly overexpressed casein kinase-2 interacting protein-1 contribute to failure of osteoblast-mediated repair for bone erosion in rheumatoid arthritis? (2013-2015, HK$3,000,000)
Research and development of triptolide-aptamer drug (2013.1-2015.12, RMB1,500,000)
Prof. Ge Zhang
The molecular mechanism of aged-related decrease of osteogenesis in osteoporosis: the effect of miR-214 derived from osteoclasts on osteoblastic activity (2015.11.1-2017.10.31, RMB300,000)
An innovative immuno-chemotherapy for triple-negative breast cancer: PD-L1 aptamer-paclitaxel conjugate (2016.7.1-2019.6.30, RMB3,000,000)
Anti-PD-L1 aptamer in combination of paclitaxel for treating triple-negative breast cancer (2016.05.03-2020.05.02, HK$3000,000)
Aptamer-modified Paclitaxel for Tumor Therapy (2014.9.4-2019.8.3, HK$2,700,000)
Skeletal role of CK2-interating Protein-1 in Regulating Osteoblastic Bone Formation: Molecular Mechanism and Reversing Osteoporosis (2013.1.1-2016.12.31, HK$753,925)
Study on molecular mechanism of bone formation reduction in aged women: Functional role of CKIP-1 (2013.1.1-2016.12.31, RMB700,000)
Establishing the bridge for translating cell-specific RNA interference to bone anabolic therapy: An aptamer-functionalized osteoblast-targeting delivery system for osteogenic siRNAs (2013.8.1-2015.8.30, RMB300,000)
Private Fund from
Gui Zhou Yi Bai
Private Fund from
Pian Zai Huang
Private Fund from
Tai De
2013ZX09301307
(Sub-project of National Science and Technology Major Projects for "Major New Drugs Innovation and Development")
Contract Study from Kunshan RNAi Institute
SCM-2015-SZTIC-003
(Science and Technology Innovation Commission of Shenzhen Municipality)
SCM-2016-SZTIC-001
(Science and Technology Innovation Commission of Shenzhen Municipality)
Private Fund from
Huabao Ltd.
Private Fund from
from Qinfeng, QFPG/14-15/01-SCMD
SCM-2013-SZTIC-001
(Science and Technology Innovation Commission of Shenzhen Municipality)
N_HKBU435/12
(NSFC-RGC)
NSFC 81272045
(NSFC)